These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37942884)

  • 1. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity.
    Bou Rjeily N; Fitzgerald KC; Mowry EM
    Mult Scler; 2024 Feb; 30(2):257-260. PubMed ID: 37942884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
    Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic.
    Zanghì A; Avolio C; Signoriello E; Abbadessa G; Cellerino M; Ferraro D; Messina C; Barone S; Callari G; Tsantes E; Sola P; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Inglese M; D'Amico E
    Neurotherapeutics; 2022 Sep; 19(5):1535-1545. PubMed ID: 36036858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
    Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
    Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
    Rolfes L; Pawlitzki M; Pfeuffer S; Nelke C; Lux A; Pul R; Kleinschnitz C; Kleinschnitz K; Rogall R; Pape K; Bittner S; Zipp F; Warnke C; Goereci Y; Schroeter M; Ingwersen J; Aktas O; Klotz L; Ruck T; Wiendl H; Meuth SG
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34261812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
    Rodriguez-Mogeda C; van Lierop ZYGJ; van der Pol SMA; Coenen L; Hogenboom L; Kamermans A; Rodriguez E; van Horssen J; van Kempen ZLE; Uitdehaag BMJ; Teunissen CE; Witte ME; Killestein J; de Vries HE
    J Neuroinflammation; 2023 Sep; 20(1):215. PubMed ID: 37752582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended interval dosing with ocrelizumab in multiple sclerosis.
    Novak F; Bajwa HM; Østergaard K; Berg JM; Madsen JS; Olsen DA; Urbonaviciute I; Illes Z; Stilund ML; Romme Christensen J; Bramow S; Sellebjerg F; Sejbaek T
    Mult Scler; 2024 Jun; 30(7):847-856. PubMed ID: 38646949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memory B cell-guided extended interval dosing of ocrelizumab in multiple sclerosis.
    Meng D; Sacco R; Disanto G; Widmer F; Jacober SLS; Gobbi C; Zecca C
    Mult Scler; 2024 Jun; 30(7):857-867. PubMed ID: 38767224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis.
    Schuckmann A; Steffen F; Zipp F; Bittner S; Pape K
    Med; 2023 Jun; 4(6):361-372.e3. PubMed ID: 37236189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    Bisecco A; Matrone F; Capobianco M; De Luca G; Filippi M; Granella F; Lus G; Marfia GA; Mirabella M; Patti F; Trojano M; Mascolo A; Copetti M; Tedeschi G; Gallo A;
    J Neurol; 2024 Feb; 271(2):699-710. PubMed ID: 37982852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients.
    Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A
    Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience.
    Zanghì A; Ferraro D; Callari G; Valentino P; Granella F; Patti F; Lus G; Bonavita S; Moretti MC; Avolio C; D'Amico E
    Curr Neuropharmacol; 2024; 22(2):339-345. PubMed ID: 37876043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
    Mancinelli CR; Scarpazza C; Cordioli C; De Rossi N; Rasia S; Turrini MV; Capra R
    Mult Scler; 2021 Apr; 27(5):790-794. PubMed ID: 32749910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic.
    van Lierop ZY; Toorop AA; van Ballegoij WJ; Olde Dubbelink TB; Strijbis EM; de Jong BA; van Oosten BW; Moraal B; Teunissen CE; Uitdehaag BM; Killestein J; Kempen ZLV
    Mult Scler; 2022 Jun; 28(7):1121-1125. PubMed ID: 34240631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA; van Lierop ZY; Gelissen LM; Hoitsma E; Zeinstra EM; van Rooij LC; van Munster CE; Vennegoor A; Mostert JP; Wokke BH; Kalkers NF; Hoogervorst EL; van Eijk JJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige L; Kloosterziel ME; Arnoldus EP; van Dijk GW; Bouvy WH; Wessels MH; Boonkamp L; Strijbis EM; van Oosten BW; De Jong BA; Lissenberg-Witte BI; Barkhof F; Moraal B; Teunissen CE; Rispens T; Uitdehaag BM; Killestein J; van Kempen ZL
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):392-400. PubMed ID: 37963723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
    Venet M; Lepine A; Maarouf A; Biotti D; Boutiere C; Casez O; Cohen M; Durozard P; Demortière S; Giorgi L; Maillart E; Mathey G; Mazzola L; Rico A; Camdessanche JP; Deiva K; Pelletier J; Audoin B
    Mult Scler; 2024 Feb; 30(2):261-265. PubMed ID: 38166437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocrelizumab (Ocrevus) for MS.
    Med Lett Drugs Ther; 2017 Jun; 59(1523):98-101. PubMed ID: 28609424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.